Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Introduction: Chronic inflammatory neuropathies are disorders caused by an immune response to peripheral nerve. They include chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN) and neuropathy associated with anti-MAG IgM monoclonal gammopathy and other less frequent neuropathies. Several immune therapies have been proven to be effective in these neuropathies even if the best therapeutic option is still unsettled. Areas covered: The authors reviewed the literature to compare the efficacy and safety of currently used immune therapies in these neuropathies. The authors also analyzed the effect of other immune suppressive agents and of biological agents including rituximab, eculizumab, natalizumab, alemtuzumab and fingolimod that were found effective in other autoimmune diseases. Expert commentary: Despite the reported efficacy of a number of new immune therapies in some patients with immune mediated neuropathies, their efficacy has not been so far confirmed in randomized controlled studies. High-dose intravenous immunoglobulin (IVIg) (and subcutaneous immunoglobulin [SCIg] for maintenance treatment), steroids and plasma exchange remain the only therapy of proven efficacy in CIDP, IVIg in MMN and, with certain limits, rituximab and, occasionally plasma exchange in neuropathy associated with anti-MAG antibodies. New biological agents are also on the horizon but their efficacy needs to be proved in controlled studies.

Original languageEnglish
Pages (from-to)755-765
Number of pages11
JournalExpert Review of Neurotherapeutics
Volume17
Issue number8
DOIs
Publication statusPublished - Aug 3 2017

Fingerprint

Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Plasma Exchange
Intravenous Immunoglobulins
Biological Factors
Therapeutics
Paraproteinemias
Immune System Diseases
Peripheral Nerves
Autoimmune Diseases
Immunoglobulins
Anti-Idiotypic Antibodies
Steroids
Safety
Rituximab
eculizumab
Natalizumab
anti-IgM
alemtuzumab
Fingolimod Hydrochloride

Keywords

  • Anti-MAG neuropathy
  • CIDP
  • immune therapies
  • IVIg
  • MMN
  • neuropathy
  • plasma exchange
  • rituximab
  • SCIg
  • steroids
  • therapy

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

@article{d5378381cbdc43deabd199a4041bea9c,
title = "Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan",
abstract = "Introduction: Chronic inflammatory neuropathies are disorders caused by an immune response to peripheral nerve. They include chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN) and neuropathy associated with anti-MAG IgM monoclonal gammopathy and other less frequent neuropathies. Several immune therapies have been proven to be effective in these neuropathies even if the best therapeutic option is still unsettled. Areas covered: The authors reviewed the literature to compare the efficacy and safety of currently used immune therapies in these neuropathies. The authors also analyzed the effect of other immune suppressive agents and of biological agents including rituximab, eculizumab, natalizumab, alemtuzumab and fingolimod that were found effective in other autoimmune diseases. Expert commentary: Despite the reported efficacy of a number of new immune therapies in some patients with immune mediated neuropathies, their efficacy has not been so far confirmed in randomized controlled studies. High-dose intravenous immunoglobulin (IVIg) (and subcutaneous immunoglobulin [SCIg] for maintenance treatment), steroids and plasma exchange remain the only therapy of proven efficacy in CIDP, IVIg in MMN and, with certain limits, rituximab and, occasionally plasma exchange in neuropathy associated with anti-MAG antibodies. New biological agents are also on the horizon but their efficacy needs to be proved in controlled studies.",
keywords = "Anti-MAG neuropathy, CIDP, immune therapies, IVIg, MMN, neuropathy, plasma exchange, rituximab, SCIg, steroids, therapy",
author = "Eduardo Nobile-Orazio and Francesca Gallia and Fabrizia Terenghi and Mariangela Bianco",
year = "2017",
month = "8",
day = "3",
doi = "10.1080/14737175.2017.1340832",
language = "English",
volume = "17",
pages = "755--765",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "8",

}

TY - JOUR

T1 - Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan

AU - Nobile-Orazio, Eduardo

AU - Gallia, Francesca

AU - Terenghi, Fabrizia

AU - Bianco, Mariangela

PY - 2017/8/3

Y1 - 2017/8/3

N2 - Introduction: Chronic inflammatory neuropathies are disorders caused by an immune response to peripheral nerve. They include chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN) and neuropathy associated with anti-MAG IgM monoclonal gammopathy and other less frequent neuropathies. Several immune therapies have been proven to be effective in these neuropathies even if the best therapeutic option is still unsettled. Areas covered: The authors reviewed the literature to compare the efficacy and safety of currently used immune therapies in these neuropathies. The authors also analyzed the effect of other immune suppressive agents and of biological agents including rituximab, eculizumab, natalizumab, alemtuzumab and fingolimod that were found effective in other autoimmune diseases. Expert commentary: Despite the reported efficacy of a number of new immune therapies in some patients with immune mediated neuropathies, their efficacy has not been so far confirmed in randomized controlled studies. High-dose intravenous immunoglobulin (IVIg) (and subcutaneous immunoglobulin [SCIg] for maintenance treatment), steroids and plasma exchange remain the only therapy of proven efficacy in CIDP, IVIg in MMN and, with certain limits, rituximab and, occasionally plasma exchange in neuropathy associated with anti-MAG antibodies. New biological agents are also on the horizon but their efficacy needs to be proved in controlled studies.

AB - Introduction: Chronic inflammatory neuropathies are disorders caused by an immune response to peripheral nerve. They include chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN) and neuropathy associated with anti-MAG IgM monoclonal gammopathy and other less frequent neuropathies. Several immune therapies have been proven to be effective in these neuropathies even if the best therapeutic option is still unsettled. Areas covered: The authors reviewed the literature to compare the efficacy and safety of currently used immune therapies in these neuropathies. The authors also analyzed the effect of other immune suppressive agents and of biological agents including rituximab, eculizumab, natalizumab, alemtuzumab and fingolimod that were found effective in other autoimmune diseases. Expert commentary: Despite the reported efficacy of a number of new immune therapies in some patients with immune mediated neuropathies, their efficacy has not been so far confirmed in randomized controlled studies. High-dose intravenous immunoglobulin (IVIg) (and subcutaneous immunoglobulin [SCIg] for maintenance treatment), steroids and plasma exchange remain the only therapy of proven efficacy in CIDP, IVIg in MMN and, with certain limits, rituximab and, occasionally plasma exchange in neuropathy associated with anti-MAG antibodies. New biological agents are also on the horizon but their efficacy needs to be proved in controlled studies.

KW - Anti-MAG neuropathy

KW - CIDP

KW - immune therapies

KW - IVIg

KW - MMN

KW - neuropathy

KW - plasma exchange

KW - rituximab

KW - SCIg

KW - steroids

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=85022213258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022213258&partnerID=8YFLogxK

U2 - 10.1080/14737175.2017.1340832

DO - 10.1080/14737175.2017.1340832

M3 - Review article

AN - SCOPUS:85022213258

VL - 17

SP - 755

EP - 765

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 8

ER -